NasdaqCM - Delayed Quote • USD
Celldex Therapeutics, Inc. (CLDX)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:20 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 7 | 6 |
| Avg. Estimate | -0.69 | -0.71 | -3.01 | -3.09 |
| Low Estimate | -0.75 | -0.76 | -3.55 | -3.93 |
| High Estimate | -0.65 | -0.67 | -2.75 | -1.76 |
| Year Ago EPS | -0.62 | -0.65 | -2.92 | -3.01 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 7 | 6 |
| Avg. Estimate | 920k | 920k | 3.15M | 2.76M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 1.6M | 1.6M | 6.5M | 6.5M |
| Year Ago Sales | 967k | 268k | 6.88M | 3.15M |
| Sales Growth (year/est) | -4.90% | 243.30% | -54.20% | -12.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.63 | -0.67 | -0.68 | -0.74 |
| EPS Actual | -0.62 | -0.65 | -0.81 | -0.83 |
| Difference | 0.01 | 0.02 | -0.13 | -0.09 |
| Surprise % | 1.60% | 3.00% | -19.10% | -12.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.69 | -0.71 | -3.01 | -3.09 |
| 7 Days Ago | -0.69 | -0.71 | -3.01 | -3.09 |
| 30 Days Ago | -0.69 | -0.71 | -3.01 | -3.09 |
| 60 Days Ago | -0.74 | -0.76 | -2.98 | -3.1 |
| 90 Days Ago | -0.75 | -0.75 | -3.09 | -3.23 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CLDX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -11.30% | -- | -- | 6.50% |
| Next Qtr. | -9.20% | -- | -- | 12.00% |
| Current Year | -3.10% | -- | -- | 5.30% |
| Next Year | -2.70% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/17/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/22/2024 |
| Maintains | Guggenheim: Buy to Buy | 2/27/2024 |
| Initiated | TD Cowen: Outperform | 12/20/2023 |
| Upgrade | Wells Fargo: Underweight to Equal-Weight | 11/10/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/6/2023 |
Related Tickers
MRUS Merus N.V.
45.04
+0.24%
JSPR Jasper Therapeutics, Inc.
20.40
-3.68%
ATXS Astria Therapeutics, Inc.
9.00
-1.85%
CABA Cabaletta Bio, Inc.
11.01
-9.61%
MLTX MoonLake Immunotherapeutics
42.49
+0.57%
AKRO Akero Therapeutics, Inc.
19.74
+4.28%
DNTH Dianthus Therapeutics, Inc.
21.50
+2.43%
VERA Vera Therapeutics, Inc.
39.65
+2.48%
SNDX Syndax Pharmaceuticals, Inc.
21.06
+2.38%
APGE Apogee Therapeutics, Inc.
47.13
+2.77%